B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies

Arthritis Research and Therapy

Volumn 15, Issue SUPPL.1, 2013, Pages

  Leandro, Maria J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD16 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; COMPLEMENT COMPONENT C1Q; FC RECEPTOR IIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; OFATUMUMAB; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANTIBODY RESPONSE; ANTIGEN BINDING; APOPTOSIS; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO CULTURE; IN VIVO STUDY; MEMORY CELL; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VACCINATION; AUTOIMMUNE DISEASE; CELL COUNT; DRUG EFFECT; DRUG RESISTANCE; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; B-LYMPHOCYTE SUBSETS; CELL COUNT; DRUG RESISTANCE; HUMANS; IMMUNOLOGIC FACTORS; TREATMENT OUTCOME;

EID: 84875534792     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3908     Document Type: Review

References (72)

1. Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol 2009, 27:267-285. 10.1146/annurev.immunol.021908.132607, 19302041.
2. Lammers AJJ, de Porto APNA, Bennink RJ, van Leeuwen EM, Biemond BJ, Goslings JC, van Marle J, ten Berge IJ, Speelman P, Hoekstra JB. Hyposplenism: comparison of different methods for determining splenic function. Am J Hematol 2012, 87:484-489. 10.1002/ajh.23154, 22488175.
3. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998, 188:1679-1689. 10.1084/jem.188.9.1679, 2212515, 9802980.
4. Fecteau JF, Cote G, Neron S. A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. J Immunol 2006, 177:3728-3736.
5. Berkowska MA, Driessen GJA, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, He B, Biermann K, Lange JF, van der Burg M, van Dongen JJ, van Zelm MC. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011, 118:2150-2158. 10.1182/blood-2011-04-345579, 3342861, 21690558.
6. Koethe S, Zander L, Koster S, Annan A, Ebenfelt A, Spencer J, Bemark M. Pivotal advance: CD45RB glycosylation is specifically regulated during human peripheral B cell differentiation. J Leukoc Biol 2011, 90:5-19. 10.1189/jlb.0710404, 21278234.
7. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 2012, 12:191-200. 3409649, 22343568.
8. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal centre founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001, 167:3610-3618.
9. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005, 105:4390-4398. 10.1182/blood-2004-11-4284, 1895038, 15701725.
10. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, Looney RJ, Sanz I, Anolik JH. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 2009, 182:5982-5993. 10.4049/jimmunol.0801859, 2746373, 19414749.
11. Lee J, Kuchen S, Fischer R, Chang S, Lipsky PE. Identification and characterization of a human CD5+ pre-naïve B cell population. J Immunol 2009, 182:4116-4126. 10.4049/jimmunol.0803391, 19299709.
12. Suryani S, Fulcher DA, Santner-Nanan B, Nanan R, Wong M, Shaw PJ, Gibson J, Williams A, Tangye SG. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood 2010, 115:519-529. 10.1182/blood-2009-07-234799, 19965666.
13. Wei C, Jung J, Sanz I. OMIP-003: phenotypic analysis of human memory B cells. Cytometry A 2011, 79:894-896. 3199331, 21796774.
14. Bemark M, Holmqvist J, Abrahamsson J, Mellgren K. Translational mini-review series on B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation-revelation of B cell developmental pathways and lineage phenotypes. Clin Exp Immunol 2011, 167:15-25.
15. Alduaji W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood 2011, 117:2993-3001. 10.1182/blood-2010-07-298356, 21209380.
16. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E, van Lier RA. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Investig 2010, 120:214-222. 10.1172/JCI40231, 2798692, 20038800.
17. Leandro MJ, Cambridge G, Ehrenstein M, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613-620. 10.1002/art.21617, 16447239.
18. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
19. Bulati M, Buffa S, Candore G, Caruso C, Dunn-Walters DK, Pellicano M, Wu YC, Colonna Romano G. B cells and immunosenescence: a focus on IgG+IgD- CD27- B cells in aged humans. Ageing Res Rev 2011, 10:274-284. 10.1016/j.arr.2010.12.002, 21185406.
20. Keren Z, Naor S, Nussbaum S, Golan K, Itkin T, Sasaki Y, Scmidt-Supprian M, Lapidot T, Melamed D. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. Blood 2011, 117:3104-3112. 10.1182/blood-2010-09-307983, 21228330.
21. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003, 48:2146-2154. 10.1002/art.11181, 12905467.
22. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008, 67:1011-1016.
23. Teng YKO, Wheater G, Hogan VE, Stocks P, Levarht EWN, Huizinag TWJ, Toes REM, van Laar JM. Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially afftects autoreactive more than protective humoral immunity. Arthritis Res Ther 2012, 14:R57. 10.1186/ar3770, 3446423, 22409963.
24. Stevenson FK, Stevenson GT. Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. Blood 2012, 119:3659-3667. 10.1182/blood-2011-11-367730, 22337721.
25. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987, 69:584-591.
26. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84:2457-2466.
27. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012, 188:3532-3541. 10.4049/jimmunol.1103693, 22368276.
28. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011, 24:203-216. 10.1016/j.beha.2011.02.009, 3113665, 21658619.
29. Beers SA, French RR, Chan HTC, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PW, Verbeek JS, Glennie MJ, Cragg MS. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2011, 115:5191-5210.
30. Vugmeyster Y, Howell K, McKeever K, Combs D, Canova-Davis E. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int Immunopharmacol 2003, 3:1477-1481. 10.1016/S1567-5769(03)00147-4, 12946444.
31. Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M, Lombardi S, Pitzalis C, Beltrami CA, Curcio F, De Vita S. Resistance to rituximab therapy and local BAFF overexpression in Sjogren's syndromerelated myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2008, 2:38-43. 10.2174/1874312900802010038, 2577948, 19088870.
32. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005, 174:817-826.
33. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM, Tedder TF. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 2005, 174:4389-4399.
34. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007, 179:3351-3361.
35. Ahuja A, Teichmann LL, Wang H, Dunn R, Kehry MR, Shlomchik MJ. An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in lupus. J Immunol 2011, 187:3888-3894. 10.4049/jimmunol.1101629, 3178685, 21873531.
36. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589. 10.1002/art.20430, 15334472.
37. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis 2008, 67:1724-1731. 10.1136/ard.2007.083162, 18250115.
38. Kamburova EG, Koenen HJPM, Boon L, Hilbrands LB, Joosten I. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant 2012, 12:341-350. 10.1111/j.1600-6143.2011.03833.x, 22070501.
39. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, Ponchel F, Emery P. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of retreatment. Arthritis Rheum 2010, 62:1273-1279. 10.1002/art.27359, 20131284.
40. Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, McGonagle D. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011, 63:603-608. 10.1002/art.30152, 21360489.
41. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011, 63:3038-3047. 10.1002/art.30466, 21618204.
42. Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology 2005, 44:561-562. 10.1093/rheumatology/keh533, 15644390.
43. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008, 58:2993-2999. 10.1002/art.23902, 18821683.
44. Mei HE, Frolich D, Giesecke C, Loddenkemper C, Reiter K, Schmidt S, Feist E, Daridon C, Tony HP, Radbruch A, Dorner T. Steady state generation of mucosal IgA+ plasmablasts is not abrogated by B cell depletion therapy with rituximab. Blood 2010, 116:5181-5190. 10.1182/blood-2010-01-266536, 20829370.
45. Roll P, Dorner T, Tony H-P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008, 58:1566-1575. 10.1002/art.23473, 18512772.
46. Palanichamy A, Muhammad K, Roll P, Kleinert S, Dorner T, Tony HP. Rituximab therapy leads to reduced imprints of receptor revision in immunoglobulin κ and λ light chains. J Rheumatol 2012, 39:1130-1138. 10.3899/jrheum.111513, 22505705.
47. Boumans MJH, Thurlings RM, Gerlag DM, Vos K, Tak PP. Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system. Arthritis Rheum 2011, 63:3187-3194. 10.1002/art.30567, 21792840.
48. Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, Treter S, Harper D, Kitamura H, Vitetta ES, Abraham S, Awwad M, White-Scharf ME, Sachs DH, Thall A, Cooper DK. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation 2001, 8:157-171. 10.1034/j.1399-3089.2001.008003157.x, 11472623.
49. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti- CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003, 12:19-28. 10.1016/S0966-3274(03)00059-5, 14551029.
50. Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology 2007, 46:29-36. 10.1093/rheumatology/kel148, 16735454.
51. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009, 11:R123. 10.1186/ar2789, 2745807, 19686595.
52. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009, 11:R131. 10.1186/ar2798, 2745815, 19715572.
53. Cioc AM, Vanderwerf SM, Peterson BA, Robu VG, Forster CL, Pambuccian SE. Rituximab-induced changes in hematolymphoid tissues found at autopsy. Am J Clin Pathol 2008, 130:604-612. 10.1309/UXLE9RHL968TER7B, 18794054.
54. Audia S, Samson M, Guy J, Janikashvili N, Fraszczak J, Trad M, Ciudad M, Leguy V, Berthier S, Petrella T, Aho-Glele S, Martin L, Maynadie M, Lorcerie B, Rat P, Cheynel N, Katsanis E, Larmonier N, Bonnotte B. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011, 118:4394-4400. 10.1182/blood-2011-03-344051, 3204911, 21876120.
55. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002, 206:519-527. 10.1078/0171-2985-00200, 12607727.
56. Mamani-Matsuda M, Cosma A, Weller S, Faili A, Staib C, Garcon L, Hermine O, Beyne-Rauzy O, Fieschi C, Pers JO, Arakelyan N, Varet B, Sauvanet A, Berger A, Paye F, Andrieu JM, Michel M, Godeau B, Buffet P, Reynaud CA, Weill JC. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 2008, 111:4653-4659. 10.1182/blood-2007-11-123844, 18316630.
57. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007, 7:402-407. 10.1111/j.1600-6143.2006.01632.x, 17241113.
58. Gelinck LBS, Teng YKO, Rimmelzwaan GF, van den Bemt BJF, Kroon FP, van Laar JM. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007, 66:1402-1403. 10.1136/ard.2007.071878, 1994303, 17881666.
59. Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O. Vacciantion against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008, 67:937-941.
60. Van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, ce Haan A, Westra J, Kallenberg CGM, Bijl M. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81. 10.1002/art.25033, 20039396.
61. Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa MI. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 2010, 12:R111. 10.1186/ar3047, 2911904, 20529331.
62. Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, Sarbagil-Maman H, Paran D, Caspi D, Elkayam O. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011, 29:1643-1648. 10.1016/j.vaccine.2010.12.072, 21211590.
63. Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, Guillevin L, Viliger PM. Protective effect of A/H1N1 vaccination in immune-mediated disease-a prospectively controlled vaccination study. Rheumatology 2012, 51:695-700. 10.1093/rheumatology/ker389, 22171015.
64. Eisenberg R, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ETL, Sullivan KE. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2013, 33:388-396. 10.1007/s10875-012-9813-x, 23064976.
65. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematopathol 2009, 49:9-13.
66. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:772-778. 10.1002/art.22400, 17328049.
67. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firenstein GS, Kalunian K, Wei N, Boyle DL. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008, 67:402-408. 2754142, 17644541.
68. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007, 56:3909-3918. 10.1002/art.22967, 18050222.
69. Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, van Laar JM, Tak PP, Wolbinj GJ. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2010, 69:409-412. 10.1136/ard.2009.109041, 19596693.
70. Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FK, Kallenberg CG, Vissink A, Ihrler S. Clinical and histological evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. Arthritis Rheum 2009, 60:3251-3256. 10.1002/art.24903, 19877054.
71. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P. BAff-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007, 56:1464-1477. 10.1002/art.22603, 17469105.
72. Thaunat O, Patey N, Gautreau C, Lechaton S, Fremeaux-Bacchi V, Dieu-Nosjean MC, Cassuto-Viguier E, Legendre C, Delahousse M, Lang P, Michel JB, Nicoletti A. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008, 85:1648-1653. 10.1097/TP.0b013e3181735723, 18551073.